✦ LIBER ✦

Results of a Phase II Multicenter Trial of Pentostatin and Rituximab in Patients with Low-Grade B-Cell Non-Hodgkin's Lymphoma: An Effective and Minimally Toxic Regimen

✍ Scribed by Drapkin, Robert; Di Bella, Nicholas J.; Faragher, David C.; Harden, Elizabeth; Matei, Carmen; Hyman, William; Mirabel, Mae; Boehm, Kristi A.; Asmar, Lina

Book ID: 119935772
Publisher: CIG Media Group, LP.
Year: 2003
Tongue: English
Weight: 165 KB
Volume: 4
Category: Article
ISSN: 1526-9655
DOI: 10.3816/clm.2003.n.026

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II Multicenter Study of Bendamusti

Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma

✍ Robinson, K. S.; Williams, M. E.; van der Jagt, R. H.; Cohen, P.; Herst, J. A.; 📂 Article 📅 2008 🏛 American Society of Clinical Oncology 🌐 English ⚖ 119 KB

Bendamustine in Patients With Rituximab-

Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study

✍ Friedberg, J. W.; Cohen, P.; Chen, L.; Robinson, K. S.; Forero-Torres, A.; La Ca 📂 Article 📅 2008 🏛 American Society of Clinical Oncology 🌐 English ⚖ 118 KB

Rituximab as first-line and maintenance

Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: Interim follow-up of a multicenter phase II trial

✍ John D Hainsworth 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 73 KB

Bendamustine Plus Rituximab Is Effective

Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma

✍ Rummel, M. J. 📂 Article 📅 2005 🏛 American Society of Clinical Oncology 🌐 English ⚖ 282 KB

Phase II study of a salvage regimen usin

Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma

✍ Yasuhiro Oki; Michinori Ogura; Harumi Kato; Ako Kikuchi; Hirofumi Taji; Yoshitoy 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB

WITHDRAWN: Addition of amifostine to CHO

WITHDRAWN: Addition of amifostine to CHOP regimen significantly reduced toxicity in patients with aggressive non-Hodgkin’s lymphoma without affecting the long term survival: Results of a phase II trial

✍ Gómez, Henry L. 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 29 KB